Sherif Ahmed Fawzi Rostom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sherif Ahmed Fawzi Rostom has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Hassan M. Faidallah
Department of Chemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
7 shared publicationsMona H. Badr
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
6 shared publicationsHeba A. Abd El Razik
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
5 shared publicationsAya Y. Rashad
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
4 shared publicationsHayam M.A. Ashour
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
4 shared publicationsHoda G. Daabees
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
4 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Design, synthesis, molecular modelling and biological evaluation of oxiconazole-based 1,2,3-triazoles as dually acting antifungal and antitumor agents
The rise of azole-resistant and the elevated prevalence of fungal infections in immuno-compromised cancer patients emphasize the necessity for strategies that can tackle both fungal resistance and tumor expansion. We postulated that the appropriate alteration of the azole pharmacophore through the inclusion of a 1,2,3-triazole ring might result in dual-acting drugs that preserve antifungal efficacy while exhibiting anticancer properties. In accordance with the aforementioned reasoning, a targeted library of oxiconazole-derived 1,2,3-triazoles was synthesized and assessed for antifungal potency, cytotoxicity, and mechanism of action. Different analogues ( 4 , 5b, 6, 8, 10, 11, 18, and 19c ) exhibited significant antifungal activity against fluconazole-sensitive C. albicans strains (S1, S2), with minimum inhibitory concentrations (MICs) ranging from 16 to 64 μg/mL, while reduced activity was observed against resistant strains (S3, S4). Compound 11 , the nearest structural counterpart of oxiconazole, proved to be the most powerful alternative, markedly suppressing ergosterol biosynthesis in both susceptible (S1) and resistant (S3) strains by 65.65% and 61.89%, respectively. Checkerboard assays demonstrated additive to indifferent relationships between 11 and fluconazole, with fractional inhibitory concentration index (FICI) values of 2 and 0.75 against S1 and S3, respectively. Docking study revealed that 11 occupied the lanosterol 14α-demethylase active pocket. In addition, compounds ( 5b, 5c, 7–9, 11, 13, 16, 17 , and 19c ) had moderate to modest cytotoxic activity against A549, Caco-2, and MCF7 cancer cells, with IC 50 values of 33.66 to 100 µM in comparison to docetaxel. Compounds ( 7, 8, and 11 ) were particularly active, with compound 11 triggering S-phase cell-cycle arrest and apoptosis in A549 cells. 11 , a chemo sensitizing adjuvant, significantly lowered the IC 50 of docetaxel in A549 and Caco-2 cells by 87.98% and 43.35%, respectively. Combination index (CI) analysis revealed strong synergism (CI = 0.16) in A549 cells and moderate synergism (CI = 0.58) in Caco-2 cells at the 50% effect level (Fa = 0.5), confirming that the combination is more effective than either agent alone. Overall, these data indicate compound 11 as a mechanistically validated dual antifungal-anticancer lead that bridges azole optimization and adjuvant oncology methods, necessitating further structure–activity optimization and in vivo testing.
- 14 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessDesign, synthesis, molecular modelling and biological evaluation of oxiconazole-based 1,2,3-triazoles as dually acting antifungal and antitumor agents
The rise of azole-resistant and the elevated prevalence of fungal infections in immuno-compromised cancer patients emphasize the necessity for strategies that can tackle both fungal resistance and tumor expansion. We postulated that the appropriate alteration of the azole pharmacophore through the inclusion of a 1,2,3-triazole ring might result in dual-acting drugs that preserve antifungal efficacy while exhibiting anticancer properties. In accordance with the aforementioned reasoning, a targeted library of oxiconazole-derived 1,2,3-triazoles was synthesized and assessed for antifungal potency, cytotoxicity, and mechanism of action. Different analogues ( 4 , 5b, 6, 8, 10, 11, 18, and 19c ) exhibited significant antifungal activity against fluconazole-sensitive C. albicans strains (S1, S2), with minimum inhibitory concentrations (MICs) ranging from 16 to 64 μg/mL, while reduced activity was observed against resistant strains (S3, S4). Compound 11 , the nearest structural counterpart of oxiconazole, proved to be the most powerful alternative, markedly suppressing ergosterol biosynthesis in both susceptible (S1) and resistant (S3) strains by 65.65% and 61.89%, respectively. Checkerboard assays demonstrated additive to indifferent relationships between 11 and fluconazole, with fractional inhibitory concentration index (FICI) values of 2 and 0.75 against S1 and S3, respectively. Docking study revealed that 11 occupied the lanosterol 14α-demethylase active pocket. In addition, compounds ( 5b, 5c, 7–9, 11, 13, 16, 17 , and 19c ) had moderate to modest cytotoxic activity against A549, Caco-2, and MCF7 cancer cells, with IC 50 values of 33.66 to 100 µM in comparison to docetaxel. Compounds ( 7, 8, and 11 ) were particularly active, with compound 11 triggering S-phase cell-cycle arrest and apoptosis in A549 cells. 11 , a chemo sensitizing adjuvant, significantly lowered the IC 50 of docetaxel in A549 and Caco-2 cells by 87.98% and 43.35%, respectively. Combination index (CI) analysis revealed strong synergism (CI = 0.16) in A549 cells and moderate synergism (CI = 0.58) in Caco-2 cells at the 50% effect level (Fa = 0.5), confirming that the combination is more effective than either agent alone. Overall, these data indicate compound 11 as a mechanistically validated dual antifungal-anticancer lead that bridges azole optimization and adjuvant oncology methods, necessitating further structure–activity optimization and in vivo testing.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 3857-3882
Biochemical and Molecular Studies on the Role of Celecoxib and Some Related Bipyrazoles in Mitigating Induced Liver Injury in Experimental Animals
Introduction: Liver fibrosis is a life-threatening disease that greatly impacts the morbidity and mortality of hepatic patients worldwide, resulting mainly as a consequence of hepatitis C, alcoholic and non-alcoholic fatty liver. COX-1 and COX-2 isozymes catalyze the synthesis of prostaglandins (PGs) and thromboxanes (TXs) from arachidonic acid causing inflammation. Owing to the scarcity of approved fibrolytic drugs available for human use, celecoxib (a selective COX-2 inhibitor) has been repurposed as a potential antifibrotic and fibrolytic agent in some chronic liver fibrosis models. Methods: The present study aims to discover a non-invasive treatment for liver fibrosis through investigating the possible ability of three celecoxib-related bipyrazole compounds HR1-3 to reverse chemically induced liver fibrosis in rats using CCl4. This fibrolytic effect was verified by histopathological, immunohistochemical, biochemical and biomolecular assays. In addition, in silico computer-aided evaluation of the compounds’ binding mode to certain molecular targets was performed, and the in silico physicochemical properties, drug likeness and pharmacokinetic parameters were predicted using web-based applications. Results: The analogs HR1-3 could serve as novel therapeutic candidates for the mitigation of liver fibrosis that deserves further derivatizations and investigations. In particular, the fluorinated analog HR3 proved to be the most active member in this study when compared to celecoxib due to its distinguished histopathological and immunohistochemical investigation results, beside its antioxidant potential, as well as its reliable effects against some biomarkers, namely, MMP-9, TGF-β 1, TIMP-1, IL-6 and TNF-α. Conclusion: Based on the obtained results, the fluorinated analog HR3 could serve as a novel therapeutic candidate for the amelioration of liver fibrosis that deserves further derivatizations and investigations.
- 1 May 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 3857-3882
Open AccessBiochemical and Molecular Studies on the Role of Celecoxib and Some Related Bipyrazoles in Mitigating Induced Liver Injury in Experimental Animals
Introduction: Liver fibrosis is a life-threatening disease that greatly impacts the morbidity and mortality of hepatic patients worldwide, resulting mainly as a consequence of hepatitis C, alcoholic and non-alcoholic fatty liver. COX-1 and COX-2 isozymes catalyze the synthesis of prostaglandins (PGs) and thromboxanes (TXs) from arachidonic acid causing inflammation. Owing to the scarcity of approved fibrolytic drugs available for human use, celecoxib (a selective COX-2 inhibitor) has been repurposed as a potential antifibrotic and fibrolytic agent in some chronic liver fibrosis models. Methods: The present study aims to discover a non-invasive treatment for liver fibrosis through investigating the possible ability of three celecoxib-related bipyrazole compounds HR1-3 to reverse chemically induced liver fibrosis in rats using CCl4. This fibrolytic effect was verified by histopathological, immunohistochemical, biochemical and biomolecular assays. In addition, in silico computer-aided evaluation of the compounds’ binding mode to certain molecular targets was performed, and the in silico physicochemical properties, drug likeness and pharmacokinetic parameters were predicted using web-based applications. Results: The analogs HR1-3 could serve as novel therapeutic candidates for the mitigation of liver fibrosis that deserves further derivatizations and investigations. In particular, the fluorinated analog HR3 proved to be the most active member in this study when compared to celecoxib due to its distinguished histopathological and immunohistochemical investigation results, beside its antioxidant potential, as well as its reliable effects against some biomarkers, namely, MMP-9, TGF-β 1, TIMP-1, IL-6 and TNF-α. Conclusion: Based on the obtained results, the fluorinated analog HR3 could serve as a novel therapeutic candidate for the amelioration of liver fibrosis that deserves further derivatizations and investigations.
- 6 November 2024
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 33 (12) , 2476-2490
Dual inhibition strategy addressing hyperuricemia and oxidative stress: design, biological evaluation and stability studies of febuxostat-probenecid mutual prodrug
- 6 November 2024
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 33 (12) , 2476-2490
Dual inhibition strategy addressing hyperuricemia and oxidative stress: design, biological evaluation and stability studies of febuxostat-probenecid mutual prodrug
- Open Access
- 3 March 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (3) , 637
The Role of Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitors in The Attenuation of CCl4-Induced Liver Fibrosis in Rats
Liver Fibrosis can be life-threatening if left untreated as it may lead to serious, incurable complications. The common therapeutic approach is to reverse the fibrosis while the intervention is still applicable. Celecoxib was shown to exhibit some antifibrotic properties in the induced fibrotic liver in rats. The present study aimed to investigate the possible antifibrotic properties in CCl4-induced liver fibrosis in male Sprague–Dawley rats compared to celecoxib of three novel methoxylated pyrazolo[3,4-d]pyrimidines. The three newly synthesized compounds were proved to be safe candidates. They showed a therapeutic effect against severe CCl4-induced fibrosis but at different degrees. The three compounds were able to partially reverse hepatic architectural distortion and reduce the fibrotic severity by showing antioxidant properties reducing MDA with increasing GSH and SOD levels, remodeling the extracellular matrix proteins and liver enzymes balance, and reducing the level of proinflammatory (TNF-α and IL-6) and profibrogenic (TGF-β) cytokines. The results revealed that the dimethoxy-analog exhibited the greatest activity in all the previously mentioned parameters compared to celecoxib and the other two analogs which could be attributed to the different methoxylation patterns of the derivatives. Collectively, the dimethoxy-derivative could be considered a safe promising antifibrotic candidate.
- 3 March 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (3) , 637
Open AccessThe Role of Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitors in The Attenuation of CCl4-Induced Liver Fibrosis in Rats
Liver Fibrosis can be life-threatening if left untreated as it may lead to serious, incurable complications. The common therapeutic approach is to reverse the fibrosis while the intervention is still applicable. Celecoxib was shown to exhibit some antifibrotic properties in the induced fibrotic liver in rats. The present study aimed to investigate the possible antifibrotic properties in CCl4-induced liver fibrosis in male Sprague–Dawley rats compared to celecoxib of three novel methoxylated pyrazolo[3,4-d]pyrimidines. The three newly synthesized compounds were proved to be safe candidates. They showed a therapeutic effect against severe CCl4-induced fibrosis but at different degrees. The three compounds were able to partially reverse hepatic architectural distortion and reduce the fibrotic severity by showing antioxidant properties reducing MDA with increasing GSH and SOD levels, remodeling the extracellular matrix proteins and liver enzymes balance, and reducing the level of proinflammatory (TNF-α and IL-6) and profibrogenic (TGF-β) cytokines. The results revealed that the dimethoxy-analog exhibited the greatest activity in all the previously mentioned parameters compared to celecoxib and the other two analogs which could be attributed to the different methoxylation patterns of the derivatives. Collectively, the dimethoxy-derivative could be considered a safe promising antifibrotic candidate.
- 1 October 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 263-279
Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in vitro biological evaluation, molecular docking and in silico ADME-T studies
- 1 October 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 263-279
Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in vitro biological evaluation, molecular docking and in silico ADME-T studies
- 28 March 2017
- Published by Wiley in Archiv der Pharmazie
- Vol. 350 (5)
Synthesis, Anti‐Inflammatory Activity, and COX‐1/2 Inhibition Profile of Some Novel Non‐Acidic Polysubstituted Pyrazoles and Pyrano[2,3‐c]pyrazoles
The synthesis and evaluation of the anti‐inflammatory activity of some structure hybrids comprising basically the 5‐hydroxy‐3‐methyl‐1‐phenyl‐4‐substituted‐1H‐pyrazole scaffold directly linked to a variety of heterocycles and functionalities, or annulated as pyrano[2,3‐c]pyrazoles, is described. According to thein vivoresults and a comprehensive structure–activity relationship study, five analogs (5,10,17,19, and27) displayed remarkable anti‐inflammatory profiles showing distinctive % protection and ED50values, especially10and27(ED5035.7 and 38.7 μmol/kg, respectively) which were nearly equiactive to celecoxib (ED5032.1 μmol/kg). Compounds10,17, and27exhibited distinctive COX‐2 inhibition with a noticeable COX‐2 selectivity (SI values 7.83, 6.87, and 7.16, respectively), close to that of celecoxib (SI 8.68). Additionally,5,10,17,19, and27proved to be gastrointestinal tract safe (0–20% ulceration) and non‐toxic, being well tolerated by the experimental animals up to 250 mg/kg orally and 80 mg/kg parenterally. Collectively, thein vivoED50values for the most potent five derivatives agree with theirin vitroCOX‐2 selectivity indices, suggesting their usefulness as selective anti‐inflammatory COX‐2 inhibitors. The bipyrazole10and the pyranopyrazole27could be considered as the most active members in this study, being nearly equiactive to celecoxib, besides their obvious selective COX‐2 inhibition, high safety margin, and predicted pharmacokinetic (ADME‐T) suitability for oral use.
- 28 March 2017
- Published by Wiley in Archiv der Pharmazie
- Vol. 350 (5)
Synthesis, Anti‐Inflammatory Activity, and COX‐1/2 Inhibition Profile of Some Novel Non‐Acidic Polysubstituted Pyrazoles and Pyrano[2,3‐c]pyrazoles
The synthesis and evaluation of the anti‐inflammatory activity of some structure hybrids comprising basically the 5‐hydroxy‐3‐methyl‐1‐phenyl‐4‐substituted‐1H‐pyrazole scaffold directly linked to a variety of heterocycles and functionalities, or annulated as pyrano[2,3‐c]pyrazoles, is described. According to thein vivoresults and a comprehensive structure–activity relationship study, five analogs (5,10,17,19, and27) displayed remarkable anti‐inflammatory profiles showing distinctive % protection and ED50values, especially10and27(ED5035.7 and 38.7 μmol/kg, respectively) which were nearly equiactive to celecoxib (ED5032.1 μmol/kg). Compounds10,17, and27exhibited distinctive COX‐2 inhibition with a noticeable COX‐2 selectivity (SI values 7.83, 6.87, and 7.16, respectively), close to that of celecoxib (SI 8.68). Additionally,5,10,17,19, and27proved to be gastrointestinal tract safe (0–20% ulceration) and non‐toxic, being well tolerated by the experimental animals up to 250 mg/kg orally and 80 mg/kg parenterally. Collectively, thein vivoED50values for the most potent five derivatives agree with theirin vitroCOX‐2 selectivity indices, suggesting their usefulness as selective anti‐inflammatory COX‐2 inhibitors. The bipyrazole10and the pyranopyrazole27could be considered as the most active members in this study, being nearly equiactive to celecoxib, besides their obvious selective COX‐2 inhibition, high safety margin, and predicted pharmacokinetic (ADME‐T) suitability for oral use.
- Open Access
- 1 January 2017
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 65 (5) , 442-454
Novel Polyfunctional Pyridines as Anticancer and Antioxidant Agents. Synthesis, Biological Evaluation and in Silico ADME-T Study
Two series of novel alkoxylated 2-oxo(imino)-3-pyridinecarbonitriles (structurally-relevant to some reported anticancer pyridines with phosphodiesterase 3A (PDE3A) inhibitory activity) were synthesized and evaluated for their in vitro differential tumor cell growth inhibitory potential against the breast MCF7, hepatocellular Hep-G2, colon CACO-2 cell lines, and a normal human foreskin fibroblast Hs27 cell line. Compounds 8, 16 and 19 displayed recognizable growth inhibitory ability and selectivity towards the breast MCF7 (LC50 19.15, 17.34 and 14.70 µM, respectively) as compared with doxorubicin (LC50 3.94 µM). Meanwhile, compounds 8, 15, 16, and 19 revealed a marginal inhibitory effect on the growth of the normal human foreskin fibroblast Hs27 cell line, beside a distinctive antioxidant potential in the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. These four compounds were further assessed for their in vitro inhibition of PDE3A (a current antitumor therapeutic target), where 16 and 19 showed moderate to weak PDE3A inhibitory as compared with milrinone, the positive control. No clear straightforward liaison between the anticancer potential and PDE3A inhibitory activity could be deduced. Computations of the predicted pharmacokinetic properties, toxicity effects (ADME-T), drug-likeness and drug scores for the newly developed compounds showed non-violations of Lipinski's RO5 and Veber's criteria for good bioavailability, with a predicted high safety profile.
- 1 January 2017
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 65 (5) , 442-454
Open AccessNovel Polyfunctional Pyridines as Anticancer and Antioxidant Agents. Synthesis, Biological Evaluation and in Silico ADME-T Study
Two series of novel alkoxylated 2-oxo(imino)-3-pyridinecarbonitriles (structurally-relevant to some reported anticancer pyridines with phosphodiesterase 3A (PDE3A) inhibitory activity) were synthesized and evaluated for their in vitro differential tumor cell growth inhibitory potential against the breast MCF7, hepatocellular Hep-G2, colon CACO-2 cell lines, and a normal human foreskin fibroblast Hs27 cell line. Compounds 8, 16 and 19 displayed recognizable growth inhibitory ability and selectivity towards the breast MCF7 (LC50 19.15, 17.34 and 14.70 µM, respectively) as compared with doxorubicin (LC50 3.94 µM). Meanwhile, compounds 8, 15, 16, and 19 revealed a marginal inhibitory effect on the growth of the normal human foreskin fibroblast Hs27 cell line, beside a distinctive antioxidant potential in the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. These four compounds were further assessed for their in vitro inhibition of PDE3A (a current antitumor therapeutic target), where 16 and 19 showed moderate to weak PDE3A inhibitory as compared with milrinone, the positive control. No clear straightforward liaison between the anticancer potential and PDE3A inhibitory activity could be deduced. Computations of the predicted pharmacokinetic properties, toxicity effects (ADME-T), drug-likeness and drug scores for the newly developed compounds showed non-violations of Lipinski's RO5 and Veber's criteria for good bioavailability, with a predicted high safety profile.